Wordt geladen...
Inhibition of AKR1C3 activation overcomes resistance to abiraterone in advanced prostate cancer
Abiraterone suppresses intracrine androgen synthesis via inhibition of CYP17A1. However, clinical evidence suggests that androgen synthesis is not fully inhibited by abiraterone and the sustained androgen production may lead to disease relapse. In the present study, we identified AKR1C3, an importan...
Bewaard in:
| Gepubliceerd in: | Mol Cancer Ther |
|---|---|
| Hoofdauteurs: | , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5222693/ https://ncbi.nlm.nih.gov/pubmed/27794047 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-16-0186 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|